SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a sharp selloff and repeated lows, with traders citing weakness across quantum stocks and concerns about high valuations, losses, and the long path to commercial adoption. Some see the decline as a buying opportunity and point to D-Waves deployments and partnerships, while others remain skeptical that near-term business progress can support the valuation.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons third-quarter results beat expectations, with strong refining profits and record operating performancesupported by elevated fuel margins amid supply disruptionsdriving the shares higher. Traders welcomed the results and shareholder-return plans, though some noted the stocks modest reaction and bearish put-heavy options activity.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Attention centers on Charters upcoming earnings and whether it can arrest broadband subscriber losses amid fiber, fixed-wireless and satellite competition, while managing its substantial debt. Bulls point to the depressed valuation, mobile growth and potential cash-flow recovery; bears see ongoing customer losses and weak fundamentals as reasons for continued caution.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A steep selloff and repeated 52-week lows are driving attention, with traders debating whether the decline reflects a still-rich valuation and concerns about consumer spending, costs, and competition. Bulls see the shares as oversold and emphasize Dutch Bros growth, while bears expect more downside.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Shares are under pressure as traders react to weak early sales for AstraZenecas competing hypertension drug, Baxfendy, and limited insurance coverage, fueling doubts about lorundrostats commercial prospects. Some investors argue the launch is still in an early coverage ramp and see upcoming data and the FDA decision as important milestones; others worry Mineralys may struggle to compete on its own.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to fresh 52-week highs has drawn attention as traders position ahead of an expected Q3 report and watch BRIUMVIs commercial ramp. Buyout and short-squeeze speculation is prominent, though others see the move as momentum into earnings rather than evidence of a deal.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazilian equities sold off sharply after Lulas reelection, weighing on NU as traders reassessed political and macroeconomic risks in its core market. The community is divided between viewing the drop as an overreaction to the election, with the business fundamentals intact, and worrying that Brazil-related risks could prolong the weakness.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Traders are weighing growth in onsemis Other end-market bucket, which includes computing and AI data-center demand, against concerns that long-term supply agreements can be changed or canceled. The discussion is split between buyers viewing the pullback as an opportunity and skeptics pointing to weak auto and industrial demand and questioning how durable the AI-related growth will be.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced profit outlook, driven by sharply higher fuel costs, are the main focus. Traders are split between concern that fuel and operating expenses will squeeze margins and optimism that resilient travel demand, premium revenue, and fare increases can offset the pressure.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas earnings and outlook are driving the discussion, with traders focused on elevated jet-fuel costs and reduced guidance as the shares fall. Some see strong revenue, resilient demand, buybacks and Aeroplans value as support, while others worry fuel pressure will weigh on profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor...

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger   

Equity

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.


Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor...

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's...

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the...

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...

Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Safety questions around zipalertinib from mid-September late-stage lung cancer results added to the pressure on the stock.&nbsp;</li><li>In December, the company plans to report both multi-dose and single-target-dose results for CLN-978, across treatment-refractory SLE, difficult-to-treat RA, and treatment-refractory Sjögren’s disease.</li><li>TD Cowen argued the recent weakness offers a chance to buy before those updates.</li></ul> Cullinan Therapeutics (CGEM) shares tumbled as much as 12% on Thursday after the company outlined fourth-quarter pipeline updates that pushed rheumatoid arthritis data later than previously signaled.The decline reflected a broader sell-off in clinical-stage biotech names and investor disappointment that additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December along with results in lupus and Sjögren’s disease.Safety questions around zipalertinib from mid-September late-stage lung cancer results added to the pressure. Grade 3 or higher adverse events were substantially higher with the combination than chemotherapy alone.At the time of writing, the stock was down 5%, after a 22% drop on Wednesday. &nbsp;<h2 class="st-heading-2">Q4 Data Calendar</h2>Cullinan said it will present multi-dose regimen data for velinotamig from an ongoing early-stage study in systemic lupus erythematosus (SLE) at the American College of Rheumatology meeting on Nov. 8.In December, the company plans to report both multi-dose and single-target-dose results for CLN-978, across treatment-refractory SLE, difficult-to-treat RA, and treatment-refractory Sjögren’s disease. Chief Executive Nadim Ahmed described the package as the most comprehensive clinical dataset to date for a drug in the category spanning those indications.The same month, Cullinan intends to share longer follow-up from the dose-escalation portion of its early-stage study of CLN-049 in relapsed or refractory acute myeloid leukemia. After a recent successful FDA meeting, the company said it is moving toward a potentially registrational mid-stage trial.<h2 class="st-heading-2">Analyst Says Buy</h2>TD Cowen, which rates the stock Buy, said the fourth-quarter slate is full of events that could help set mid-stage plans for CLN-978 in lupus, RA, and Sjögren’s and test how durable CLN-049 looks in relapsed or refractory AML. The firm argued the recent weakness offers a chance to buy before those updates.<h2 class="st-heading-2">How Did CGEM Retail Traders React?</h2>On Stocktwits, retail sentiment around CGEM stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said the selloff doesn’t match the news.<stembedurl>https://stocktwits.com/ImFullyTorqued/message/665015963</stembedurl><a href="https://stocktwits.com/symbol/CGEM">CGEM stock</a> has gained 55% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kytx-stock-reverses-gains-after-one-year-cell-therapy-trial-data-but-ceo-says-disease-burden-justifies-a-premium-price/cZMJ9W5RB9t">KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Cullinan Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Cullinan Oncology Inc

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$15.03
Prev Close	$15.45
Open	$15.38
Dividend Yield	N/A
50-Day Moving Average	$17.91
Beta	1.30
Avg. Volume	1.23M
PE Ratio	-4.43

52-Week High	$23.19
52-Week Low	$6.73
Market Capitalization	$967.25M
EPS (Annual)	-$3.72
Price to Book	3.02
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGEM Fundamentals